EPISODE · Apr 8, 2024 · 44 MIN
Dr. Ira Spector, PhD - CEO, Co-Founder, SFA Therapeutics - Novel Microbiome Derived Immunomodulating Drugs
from Progress, Potential, and Possibilities Podcast / Show · host Ira Pastor / Dr. Ira Spector
Send us Fan MailDr. Ira Spector, PhD is CEO and a Co-Founder of SFA Therapeutics ( https://sfatherapeutics.com/ ), a microbiome-derived biopharma company focused on new advancements in the treatment inflammatory diseases. Dr. Spector is an experienced drug developer, with over 30 years of experience. He has helped develop 34 approved drugs, including Enbrel, Effexor, Protonix, Prevenar-13, Mylotarg at Wyeth/Pfizer, where he was Vice President of Clinical Operations and Vice-Chief of Development. At Allergan, Dr. Spector helped develop Ozurdex for Diabetic Macular Edema and Retinal Venous Occlusion, Botox for Overactive Bladder, Botox for Chronic Migraine, Juvederm XL and Botox for Cerebral Palsy. Prior to Wyeth, he was Vice President and Partner at the PA Consulting Group. Before founding SFA Therapeutics, Dr. Spector was Executive Vice President of Analytics & Consulting at ICON. Dr. Spector holds BS degrees in Physics and Electrical Engineering from Washington University, where he was a Langsdorf Fellow, an MBA from Drexel University, and a PhD in Health Sciences from UMDNJ. Support the show
What this episode covers
Send us Fan Mail Dr. Ira Spector, PhD is CEO and a Co-Founder of SFA Therapeutics ( https://sfatherapeutics.com/ ), a microbiome-derived biopharma company focused on new advancements in the treatment inflammatory diseases. Dr. Spector is an experienced drug developer, with over 30 years of experience. He has helped develop 34 approved drugs, including Enbrel, Effexor, Protonix, Prevenar-13, Mylotarg at Wyeth/Pfizer, where he was Vice President of Clinical Operations and Vice-Chief of Developm...
NOW PLAYING
Dr. Ira Spector, PhD - CEO, Co-Founder, SFA Therapeutics - Novel Microbiome Derived Immunomodulating Drugs
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m